• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异源 ChAdOx1-nCoV19 和 BNT162b2 疫苗接种的安全性和免疫原性：异源 COVID-19 疫苗接种结果的荟萃分析。

Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.

机构信息

Institute of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing 211198, PR China.

Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing 210008, PR China.

出版信息

Vaccine. 2023 May 2;41(18):3003-3010. doi: 10.1016/j.vaccine.2023.03.056. Epub 2023 Mar 30.

DOI:10.1016/j.vaccine.2023.03.056
PMID:37037708
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10060199/
Abstract

INTRODUCTION

Here, we systematically assessed the safety and immunogenicity of the heterologous ChAd/BNT vaccination regimens.

MATERIALS AND METHODS

We evaluated the immunogenicity by the geometric mean titers ratio (GMTR) of the neutralizing antibody and anti-spike IgG. The safety of heterologous ChAd/BNT vaccination was evaluated using the pooled risk ratios (RRs) calculated by the random-effects model about the adverse events. Our study was registered with PROSPERO, CRD42021265165.

RESULTS

Eleven studies were included in the analyses. Compared to the homologous ChAd/ChAd vaccination, the heterologous ChAd/BNT vaccination showed significantly higher immunogenicity in terms of the neutralizing antibody and GMTR of anti-spike IgG, but at the same time displayed higher incidence of total adverse reactions, especially for the local adverse reactions. Moreover, heterologous ChAd/BNT vaccination showed similar immunogenicity to the homologous BNT/BNT vaccination (GMTR of neutralizing antibody and anti-spike IgG) and similar safety.

DISCUSSION

Heterologous ChAd/BNT vaccination showed robust immunogenicity and tolerable safety.

摘要

简介

本研究系统评估了异源 ChAd/BNT 疫苗接种方案的安全性和免疫原性。

材料与方法

通过中和抗体和抗刺突 IgG 的几何平均滴度比（GMTR）评估免疫原性。采用随机效应模型计算不良事件的汇总风险比（RR）来评估异源 ChAd/BNT 疫苗接种的安全性。本研究已在 PROSPERO 上注册，注册号为 CRD42021265165。

结果

纳入的 11 项研究进行了分析。与同源 ChAd/ChAd 疫苗接种相比，异源 ChAd/BNT 疫苗接种在中和抗体和抗刺突 IgG 的 GMTR 方面表现出更高的免疫原性，但同时也显示出更高的总不良反应发生率，尤其是局部不良反应。此外，异源 ChAd/BNT 疫苗接种在中和抗体和抗刺突 IgG 的 GMTR 方面与同源 BNT/BNT 疫苗接种具有相似的免疫原性和安全性。

讨论

异源 ChAd/BNT 疫苗接种具有良好的免疫原性和可耐受的安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2956/10060199/c083ac531ffe/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2956/10060199/1027daab79a2/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2956/10060199/c083ac531ffe/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2956/10060199/1027daab79a2/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2956/10060199/c083ac531ffe/gr2_lrg.jpg

相似文献

1
Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.异源 ChAdOx1-nCoV19 和 BNT162b2 疫苗接种的安全性和免疫原性：异源 COVID-19 疫苗接种结果的荟萃分析。
Vaccine. 2023 May 2;41(18):3003-3010. doi: 10.1016/j.vaccine.2023.03.056. Epub 2023 Mar 30.
2
Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.腺病毒载体疫苗和 mRNA COVID-19 疫苗异源与同源加强免疫接种程序的免疫原性和安全性：系统评价。
Infect Dis Poverty. 2022 May 13;11(1):53. doi: 10.1186/s40249-022-00977-x.
3
Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study.血液透析患者中 ChAd/BNT 异源疫苗与同源 BNT/BNT 和 ChAd/ChAd SARS-CoV-2 疫苗相比的体液免疫原性和耐受性：一项多中心前瞻性观察研究。
J Nephrol. 2022 Jun;35(5):1467-1478. doi: 10.1007/s40620-022-01247-7. Epub 2022 Jan 27.
4
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.腺病毒载体新冠疫苗和 mRNA 新冠疫苗序贯和同源加强接种的安全性和免疫原性比较（Com-COV）：一项单盲、随机、非劣效性试验。
Lancet. 2021 Sep 4;398(10303):856-869. doi: 10.1016/S0140-6736(21)01694-9. Epub 2021 Aug 6.
5
Binding and neutralizing antibody levels and vaccine efficacy/effectiveness compared between heterologous and homologous primary series COVID-19 vaccination: A systematic review and meta-analysis.比较异源和同源初级系列 COVID-19 疫苗接种的结合和中和抗体水平以及疫苗效力/效果：系统评价和荟萃分析。
Asian Pac J Allergy Immunol. 2022 Dec;40(4):321-336. doi: 10.12932/AP-121122-1501.
6
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.在英国（Com-COV2）进行的包含 mRNA、病毒载体和蛋白佐剂疫苗的异源 COVID-19 初级疫苗接种的免疫原性、安全性和反应原性：一项单盲、随机、2 期、非劣效性试验。
Lancet. 2022 Jan 1;399(10319):36-49. doi: 10.1016/S0140-6736(21)02718-5. Epub 2021 Dec 6.
7
Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay.比较异源和同源 COVID-19 疫苗接种：抗体衰减的纵向研究。
Viruses. 2023 May 13;15(5):1162. doi: 10.3390/v15051162.
8
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.Com-COV2 研究中异源 COVID 疫苗接种方案中的免疫应答持久性 - 一项纳入 mRNA、病毒载体和蛋白佐剂疫苗的单盲、随机试验。
J Infect. 2023 Jun;86(6):574-583. doi: 10.1016/j.jinf.2023.03.027. Epub 2023 Apr 6.
9
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.在英国，使用不同的第三剂 COVID-19 疫苗接种方案进行同源和异源加强免疫后免疫应答的持久性：COV-BOOST 试验的 8 个月分析。
J Infect. 2023 Jul;87(1):18-26. doi: 10.1016/j.jinf.2023.04.012. Epub 2023 Apr 20.
10
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.在英国，两剂 ChAdOx1 nCov-19 或 BNT162b2 疫苗接种后，作为第三剂加强针接种 7 种 COVID-19 疫苗后免疫原性的持久性：COV-BOOST 试验的三个月分析。
J Infect. 2022 Jun;84(6):795-813. doi: 10.1016/j.jinf.2022.04.018. Epub 2022 Apr 9.

引用本文的文献

1
Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used.根据所使用疫苗区分的新冠疫苗接种后头痛的表型比较。
Vaccines (Basel). 2025 Jan 23;13(2):113. doi: 10.3390/vaccines13020113.
2
Impact of the COVID-19 vaccination campaigns in Argentina during 2021: An observational quantification of the death probability for confirmed cases in Buenos Aires province.2021年阿根廷新冠疫苗接种活动的影响：布宜诺斯艾利斯省确诊病例死亡概率的观察性量化分析
Heliyon. 2024 Feb 12;10(5):e26310. doi: 10.1016/j.heliyon.2024.e26310. eCollection 2024 Mar 15.

本文引用的文献

1
Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial.异源 ChAdOx1/BNT162b2 疫苗接种比同源 ChAdOx1 疫苗接种诱导更强的免疫反应：实用、多中心、三臂、部分随机的 HEVACC 试验。
EBioMedicine. 2022 Jun;80:104073. doi: 10.1016/j.ebiom.2022.104073. Epub 2022 May 23.
2
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2.同源两剂 ChAdOx1 与 ChAdOx1 和 BNT162b2 异源疫苗接种的疗效和安全性比较。
Nat Commun. 2022 Mar 23;13(1):1639. doi: 10.1038/s41467-022-29301-9.
3
Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection.
从新冠病毒奥密克戎感染中康复后的中和情况
N Engl J Med. 2022 May 5;386(18):1764-1766. doi: 10.1056/NEJMc2201607. Epub 2022 Mar 23.
4
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎（B.1.1.529）变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
5
SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons.接种疫苗者和康复者血清中对严重急性呼吸综合征冠状病毒2奥密克戎变种的中和作用
N Engl J Med. 2022 Feb 17;386(7):698-700. doi: 10.1056/NEJMc2119236. Epub 2022 Jan 12.
6
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.奥密克戎变异株对 SARS-CoV-2 表现出明显的抗体逃逸。
Nature. 2022 Feb;602(7898):676-681. doi: 10.1038/s41586-021-04388-0. Epub 2021 Dec 23.
7
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.恢复期和疫苗血清对 SARS-CoV-2 奥密克戎变体的活性。
Nature. 2022 Feb;602(7898):682-688. doi: 10.1038/s41586-022-04399-5. Epub 2021 Dec 31.
8
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.奥密克戎能广泛但不完全地逃避辉瑞 BNT162b2 的中和作用。
Nature. 2022 Feb;602(7898):654-656. doi: 10.1038/s41586-021-04387-1. Epub 2021 Dec 23.
9
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.奥密克戎逃避了大多数现有的 SARS-CoV-2 中和抗体。
Nature. 2022 Feb;602(7898):657-663. doi: 10.1038/s41586-021-04385-3. Epub 2021 Dec 23.
10
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.